TY - JOUR
T1 - Cysteamine Isobionic-Amide Complex Versus Kligman’s Formula for the Treatment of Melasma
T2 - Equal Efficacy and Rapid Onset of Action
AU - Sachdev, Mukta
AU - Grimes, Pearl E.
AU - Callender, Valerie
AU - Hartman, Corey L.
AU - Taylor, Susan C.
AU - Elbuluk, Nada
AU - Badawi, Ashraf
AU - Funasaka, Yoko
AU - Lim, Joyce
AU - Ng, Chau Yee
AU - Desai, Seemal R.
N1 - Publisher Copyright:
Copyright © 2024.
PY - 2024/2
Y1 - 2024/2
N2 - Background: Modified Kligman’s formula (mKF) is the gold standard treatment for melasma; however, its prolonged use is not recommended due to side effects. Cysteamine is a potent, safe, and effective depigmenting agent. Here, we conducted a double-blind, randomized, and placebo-controlled clinical trial to assess the efficacy of cysteamine isobionic-amide — a complex with enhanced depigmenting efficacy — and compared it to mKF for the treatment of melasma. Methods: This study involved a total of 80 patients divided into 3 groups: cysteamine-isobionic amide, placebo, or mKF. The modified Melasma Area Severity Index (mMASI) score and spectrophotometric evaluation were conducted at baseline, week 4, week 8, and week 16. Dermatological assessment, patients’ feedback, and satisfaction including quality-of-life scores were also collected. Results: At week 4, cysteamine isobionic-amide and mKF groups showed an equivalent onset of action in terms of mMASI and skin pigmentation contrast reduction. The 2 groups significantly reduced melasma severity and improved the overall skin condition with a comparable efficacy at week 16. Quality of life of melasma patients was significantly improved in the cysteamine isobionic-amide group at week 8 and further at week 16 (P<0.001) compared to the mKF group. Patients’ feedback and satisfaction were higher with the cysteamine isobionic-amide product compared to mKF. Conclusion: Cysteamine isobionic-amide provided a rapid onset of action and was as effective as the mKF for the treatment of melasma. The data suggest that cysteamine isobionic-amide could potentially be an acceptable alternative to mKF for the long-term treatment of melasma.
AB - Background: Modified Kligman’s formula (mKF) is the gold standard treatment for melasma; however, its prolonged use is not recommended due to side effects. Cysteamine is a potent, safe, and effective depigmenting agent. Here, we conducted a double-blind, randomized, and placebo-controlled clinical trial to assess the efficacy of cysteamine isobionic-amide — a complex with enhanced depigmenting efficacy — and compared it to mKF for the treatment of melasma. Methods: This study involved a total of 80 patients divided into 3 groups: cysteamine-isobionic amide, placebo, or mKF. The modified Melasma Area Severity Index (mMASI) score and spectrophotometric evaluation were conducted at baseline, week 4, week 8, and week 16. Dermatological assessment, patients’ feedback, and satisfaction including quality-of-life scores were also collected. Results: At week 4, cysteamine isobionic-amide and mKF groups showed an equivalent onset of action in terms of mMASI and skin pigmentation contrast reduction. The 2 groups significantly reduced melasma severity and improved the overall skin condition with a comparable efficacy at week 16. Quality of life of melasma patients was significantly improved in the cysteamine isobionic-amide group at week 8 and further at week 16 (P<0.001) compared to the mKF group. Patients’ feedback and satisfaction were higher with the cysteamine isobionic-amide product compared to mKF. Conclusion: Cysteamine isobionic-amide provided a rapid onset of action and was as effective as the mKF for the treatment of melasma. The data suggest that cysteamine isobionic-amide could potentially be an acceptable alternative to mKF for the long-term treatment of melasma.
UR - http://www.scopus.com/inward/record.url?scp=85184344578&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85184344578&partnerID=8YFLogxK
U2 - 10.36849/JDD.7428
DO - 10.36849/JDD.7428
M3 - Article
C2 - 38306138
AN - SCOPUS:85184344578
SN - 1545-9616
VL - 23
SP - 9
EP - 16
JO - Journal of Drugs in Dermatology
JF - Journal of Drugs in Dermatology
IS - 2
ER -